AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth Care
Bone Marrow TransplantationHematopoietic Stem Cell TransplantationTransplantation, HomologousStem Cell TransplantationBone MarrowTransplantation, AutologousBone Marrow CellsGraft vs Host DiseaseTransplantation ConditioningStem CellsPeripheral Blood Stem Cell TransplantationLiver TransplantationHematopoietic Stem CellsTransplantation ChimeraHematologic NeoplasmsWhole-Body IrradiationBone and BonesTissue DonorsGraft SurvivalBusulfanTreatment OutcomeLeukemiaKidney TransplantationHistocompatibility TestingMesenchymal Stem Cell TransplantationHistocompatibilityRecurrenceAnemia, AplasticCord Blood Stem Cell TransplantationCombined Modality TherapyRemission InductionCell TransplantationCyclophosphamideImmunosuppressive AgentsBone Marrow PurgingMultiple MyelomaTransplantation, IsogeneicHematopoiesisRetrospective StudiesCell DifferentiationTime FactorsLeukemia, Myeloid, AcuteBone Marrow DiseasesMyeloablative AgonistsHeart TransplantationTransplantation ImmunologyMelphalanGraft RejectionEmbryonic Stem CellsHepatic Veno-Occlusive DiseaseGraft vs Leukemia EffectMice, Inbred C57BLSurvival AnalysisHematopoietic Stem Cell MobilizationLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLung TransplantationAdult Stem CellsAntigens, CD34Precursor Cell Lymphoblastic Leukemia-LymphomaMyelodysplastic SyndromesAntineoplastic Combined Chemotherapy ProtocolsSurvival RateDisease-Free SurvivalLymphoma, Non-HodgkinHematologic DiseasesHLA AntigensImmunosuppressionBone Marrow ExaminationLymphocyte DepletionLymphocyte TransfusionGraft vs Tumor EffectOrgan TransplantationAcute DiseaseBone RemodelingFollow-Up StudiesGranulocyte Colony-Stimulating FactorCells, CulturedMesenchymal Stromal CellsT-LymphocytesChimerismLeukemia, MyeloidRadiation ChimeraBone Marrow NeoplasmsFlow CytometrySalvage TherapyColony-Forming Units AssaySevere Combined ImmunodeficiencyCytarabineVidarabineCytomegalovirus InfectionsStem Cell NicheCyclosporinePluripotent Stem CellsTransplantationCell LineageAntilymphocyte SerumIslets of Langerhans TransplantationCarmustinePrognosisEtoposide
AllogeneicPeripheral bloodMajorTreatmentPatientsAutologousUmbilicalCurativeGraftPatientsTherapy
Allogeneic2
  • Globally, it is estimated that 120 000 corneal transplantations and 18 000 transplantations of allogeneic haematopoietic progenitor cells took place in the year 2000. (who.int)
  • Because of the patient's risk status, the physicians intended to perform allogeneic stem cell transplantation after induction and consolidation chemotherapy, which was scheduled to end in January 2013, and a conditioning chemotherapy regimen, which was planned to be given in March. (cdc.gov)
Peripheral blood2
  • 1 This includes human cells for transplantation such as haematopoietic stem cells from bone marrow, peripheral blood or cord blood. (who.int)
  • Here, we report transmission of dengue virus to a peripheral blood stem cell recipient by a donor who had recently traveled to an area to which the virus is endemic. (cdc.gov)
Major2
  • The persistent and widening gap between patients' need for organs and the number available for transplantation has become a major concern to many Member States. (who.int)
  • Hematopoietic stem cell transplantation has become a major treatment option for patients with hematopoietic malignancies and immune deficiencies. (cdc.gov)
Treatment1
  • Moreover, for patients who have kidney failure, access to transplantation is reduced when funds are spent on other forms of treatment that are less cost-effective. (who.int)
Patients1
  • Even between countries which have similar levels of health resources, patients' access to transplantation also varies. (who.int)
Autologous3
  • The stem cells in autologous transplants come from the same person who will get the transplant, so the patient is their own donor. (cancer.org)
  • An advantage of an autologous stem cell transplant is that you're getting your own cells back. (cancer.org)
  • The current standard of care for patients with multiple myeloma (MM) is the use of drugs such as bortezomib, thalidomide and lenalidomide followed by autologous stem cell transplantation (ASCT). (haematologica.org)
Umbilical3
Curative1
  • However, whether BMMSC and BMMNC from bone marrow have any difference of curative effect for the treatment of spastic CP remains unreported. (biomedcentral.com)
Graft1
  • When you get your own stem cells back, you don't have to worry about them (called the engrafted cells or the "graft") being rejected by your body. (cancer.org)
Patients1
Therapy2
  • In a typical stem cell transplant for cancer, a person first gets very high doses of chemo , sometimes along with radiation therapy , to try to kill all the cancer cells. (cancer.org)
  • After you get high doses of chemo and/or radiation as your myeloablative therapy, the stem cells are thawed and given back to you. (cancer.org)